NovaBay Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
NovaBay Pharmaceuticals's earnings have been declining at an average annual rate of -14.7%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 11.2% per year.
Key information
-14.7%
Earnings growth rate
24.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 11.2% |
| Return on equity | -290.9% |
| Net Margin | -113.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How NovaBay Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 15 | -17 | 13 | 0 |
| 30 Sep 23 | 15 | -16 | 15 | 0 |
| 30 Jun 23 | 15 | -20 | 14 | 0 |
| 31 Mar 23 | 14 | -18 | 15 | 0 |
| 31 Dec 22 | 14 | -16 | 15 | 0 |
| 30 Sep 22 | 14 | -9 | 16 | 0 |
| 30 Jun 22 | 13 | -5 | 17 | 0 |
| 31 Mar 22 | 12 | -5 | 17 | 0 |
| 31 Dec 21 | 10 | -7 | 15 | 0 |
| 30 Sep 21 | 9 | -7 | 13 | 0 |
| 30 Jun 21 | 8 | -8 | 13 | 0 |
| 31 Mar 21 | 10 | -11 | 12 | 0 |
| 31 Dec 20 | 10 | -11 | 12 | 0 |
| 30 Sep 20 | 10 | -13 | 13 | 0 |
| 30 Jun 20 | 9 | -10 | 12 | 0 |
| 31 Mar 20 | 7 | -8 | 12 | 0 |
| 31 Dec 19 | 7 | -10 | 14 | 0 |
| 30 Sep 19 | 8 | -8 | 15 | 0 |
| 30 Jun 19 | 10 | -10 | 17 | 0 |
| 31 Mar 19 | 11 | -9 | 19 | 0 |
| 31 Dec 18 | 13 | -7 | 19 | 0 |
| 30 Sep 18 | 15 | -4 | 19 | 0 |
| 30 Jun 18 | 16 | -5 | 20 | 0 |
| 31 Mar 18 | 17 | -6 | 21 | 0 |
| 31 Dec 17 | 18 | -7 | 22 | 0 |
| 30 Sep 17 | 16 | -10 | 23 | 0 |
| 30 Jun 17 | 15 | -11 | 22 | 0 |
| 31 Mar 17 | 14 | -12 | 21 | 1 |
| 31 Dec 16 | 12 | -13 | 19 | 1 |
| 30 Sep 16 | 9 | -16 | 20 | 2 |
| 30 Jun 16 | 7 | -17 | 20 | 4 |
| 31 Mar 16 | 6 | -19 | 20 | 5 |
| 31 Dec 15 | 4 | -19 | 19 | 6 |
| 30 Sep 15 | 3 | -19 | 15 | 7 |
| 30 Jun 15 | 2 | -18 | 12 | 8 |
| 31 Mar 15 | 1 | -16 | 10 | 11 |
| 31 Dec 14 | 1 | -15 | 8 | 9 |
| 30 Sep 14 | 1 | -15 | 7 | 20 |
| 30 Jun 14 | 2 | -14 | 6 | 17 |
| 31 Mar 14 | 3 | -16 | 6 | 12 |
| 31 Dec 13 | 3 | -16 | 6 | 12 |
| 30 Sep 13 | 4 | -14 | 7 | 0 |
| 30 Jun 13 | 7 | -10 | 7 | 0 |
Quality Earnings: NBY is currently unprofitable.
Growing Profit Margin: NBY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NBY is unprofitable, and losses have increased over the past 5 years at a rate of 14.7% per year.
Accelerating Growth: Unable to compare NBY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NBY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.8%).
Return on Equity
High ROE: NBY has a negative Return on Equity (-290.89%), as it is currently unprofitable.